Healthcare charges in the United States have gone too high in the recent years compared to 1990s and before. Records show that $933 billion more was spent on healthcare in 2013 compared to 1996. Part of this figure could be attributed to an increase in population, but the effect of rising medical costs cannot be ignored. Aging is also a factor that contributes to increased doctor visits and a consequent increase in healthcare expenditure.
The JAMA Report
JAMA recently published a report on the analysis of expenditures related to healthcare. One peculiar thing about the report was that Americans were not seen to have changed the frequency in which they sought for medical services over the years. This means that besides the increase in population and the long life expectancy in America, the other prominent healthcare expenditure driver is increased charges. Gerard Anderson of the Bloomberg School of Public Health argued that prices shape the spending curve; the higher the cost, the higher the expenditure will be. Although Gerard took no active role in the 2013 research, he was part of a similar undertaking in 2003. He has been consistent since then that it is the prices that escalate spending, with the recent survey vindicating his claim and more
Joseph Dieleman is of the opinion that different diseases come with various costs. Joseph, one of the senior professionals in the study, gave an example of diabetes whereby about $44 billion out of $64 billion was spent on pharmaceuticals. That said, it is clear that prevalence of diabetes has had a substantial impact on Americans’ expenditure. Another major finding in the research was that even though the duration of patients’ hospital stay has reduced significantly, the cost associated with it has remained stagnant. Joseph Dieleman explained that this was an effect of the increase in daily hospital charges.
The Role of Lefkofsky
Eric Lefkofsky is a co-founder of several firms including Tempus. The 48 years old native of Michigan has been on the front line in trying to find solutions to cancer-related problems. As the CEO of Tempus, Eric has played a key role in ensuring that clinical data on cancer patients is available for physicians’ future use.
Tempus was established only a couple of years back, and to this end, the firm is doing a wonderful job. Eric has led the company in getting partnership deals with institutions like the University of Michigan- his alma mater, Northwestern’s Lurie Cancer Center, and Cleveland Clinic among others. His passion towards helping cancer patients is driven by a personal experience with a cancer patient.
Modern medicine keeps on advancing each day. One medicine that has been very effective in carrying out a number of procedures has been Rapamycin or Sirolimus. Among the many uses of this drug include the treatment of uncommon lung diseases, acts as a coat for coronary stents, and lastly helps in preventing organ transplant rejection.Rapamycin, however, is not a new medicine in the world. This drug was discovered in 1972; however, it was majorly used as an anti-fungal agent. With the advancement in research operations, this drug was discovered to have a lot of benefits including being a great antiproliferative and immunosuppressive. It is as a result of these features that physicians and researchers such as Mikhail Blagosklonny have endorsed it for the treatment of cancer. The following are some of the benefits of Rapamycin according to Mikhail Blagosklonny.
Helps in Treating Patients With Hemolytic-Uremic Syndrome
Hemolytic-uremic syndrome is a condition caused due to the combination of kidney failure, low platelet count, and anemia. This condition is fatal as it may results in renal failure hence leading a patient to be dependent on dialysis all of his or her lifetime. The only preventative cure for this condition is always through kidney transplants. Unlike with calcineurin inhibitors, Rapamycin has a high probability of helping you succeed in the transplant operations as it lowers the toxicity levels in your kidneys.
Treatment of Cancer
Mikhail Blagosklonny is a lead researcher when it comes to cancer. According to his research, Rapamycin’s antiproliferative properties are what helps this drug to be effective in the treatment of cancer. This drug works in two ways; first, it helps boosts our body’s immunity response. Secondly, its effects help to suppress the growth of the cancer tumor thus helping reduce the risks of cancer in patients and more so those undergoing organ transplants.
About Mikhail Blagosklonny and his Plan for Oncology
Mikhail Blagosklonny is one of the most respected scientists in the field of oncology. With cancer being one of the world’s biggest medical menaces, Mikhail Blagosklonny, through his researches, is committed to helping patients and their family ease on the cancer burden. Currently, Dr. Mikhail Blagosklonny is a professor, editor, and researcher at New York’s Rosewell Park Cancer Institute in Buffalo where he also gets to play his editorial duties at OncorTarget an online oncology publication.Dr. Mikhail Blagosklonny has to his name a number of published research works. His specialty is in the area of cancer and the effects of aging. Mikhail Blagosklonny is seeking to establish how these two areas can be merged to help come up with an effective cure for cancer. So far the progress is good if the OncorTarget publication is anything to go by. This publication has been able to attract many online readers thus creating a rich source of affordable information to both researchers and the general public leading to improved quality of life.Going into the future, Mikhail Blagosklonny has more plans not only for himself but also for his publication. He seeks to improve the quality of life and make life more bearable for cancer patients and their families by creating a cure and making the cancer information available.
A new Oncotarget article suggests that gut homeostasis plays a crucial role in the bodies of aging individuals. It also suggests that a mTOR specific inhibitor known as rapamycin has enhanced longevity in diverse evolutionary species. The inhibitor reduces the rate at which proliferation takes place in the intestinal cells. Rapamycin also slows down the expansion of microbes in aging guts. It keeps the stem cells active by inhibiting mTOR. These results are used in explaining how lifespan and healthspan can be extended in Drosophila.
IntegraGen’s New EPOC Study
In a move to avail results of a new clinical trial online, IntegraGen released new publication on the Oncotarget online journal. The company’s top scientists got the results after they analyzed miR-31-3p expression in patients’ tumor samples. The publication also explains the relationship between the efficacy of anti-EGFR treatment and miR-31-3p expression. It also explains the findings of the clinical study known as the NEW EPOC Study.Prof. John Bridgewater, a medical oncologist, partnered with other researchers in authoring the report of this innovative study. Prof. Bridgewater, who was also an investigator in the study, said that his team is honored to continue availing clinical research from the New EPOC Study. He mentioned that the data emancipates clinicians on therapies for metastatic colorectal cancer. The data helps in advancing cancer research and enhancing the healthspan and lifespan of patients with metastatic colorectal cancer.IntraGen’s molecular diagnostics director, Yann Gaston-Mathé, pointed out that the study is a manifestation of his company’s commitment to developing precision medicine therapies. Besides posting an article on Oncotarget, IntraGen signed a licensing deal together with CEBRA Laboratories. The deal allows the two companies to collaborate in developing a test that can be used in measuring miR-31-3p expression.
With an impact factor of 5.168, Oncotarget has gained recognition in the field of medicine as an open access and weekly peer-reviewed journal. Its publications cover scientific and clinical research on oncology. Since its release in 2010, Andrei Gudkov and Mikhail Blagosklonny have been serving as the senior editors. Oncotarget’s publications are usually indexed and abstracted in Scopus, Index Medicus/ PubMed, Science Citation Index Expanded and BIOSIS Previews.
Oncotarget is a medical journal that is peer reviewed on a weekly basis. The journal documents research done on all matters that pertain to oncology. It is open for access by all. The first publication was made in 2010 by the impact journals who couple as its publishers. Its two editors in chief are all Doctors from the Roswell Park Cancer Institute. The Oncotarget acts as a multidisciplinary journal publishing and publishes its content every week. For the last ten years that the journal has been providing information to its readers, it has attained a reputation as a reliable and efficient oncology journal.
In 2016, Oncotarget journal was ranked among the top 50 oncology journals by the SC Imago. The SC Imago lists journals on a scholarly topic from the available public rankings in the Scopus data. The mission of the journal is to avail scientific evidence in due time and to give an insightful peer review. It uses an insightful review in its attempt to maximize the research impact. Oncotarget facilitates quick sharing of any extraordinary discovery in the medicinal field. It has made great strides in removing the borders that have long been in existence between different specialties. The journal works to promote the application of both basic and clinical science in fighting diseases.
Due to the success attributed to the Oncotarget journal, it has been able to launch other sections. These parts include neuroscience, cardiology, pharmacology, immunology, cell biology, endocrinology, metabolism among other topics. All these components use the same submission procedures. The journal continues to rise in popularity among various readers due to the insightful, creative and punctual release of data.
Oncotarget is one of the main sponsors of the Gordon Research Conference. According to the BIOXBIO, the journal had an impact factor of 5.008 in the 2015/2016 year generating a total of 10452 citations. The high impact factor shows the frequency of citations of its articles in a given year. The high impact factor also indicates the scholarly importance attached to the journal at the researchgate.net. In its first year of ranking, Oncotarget got a rank of 4.78.
To know more click here
Eric Lefkosky is a person with a good heart, a character that is rare to find in many people. Above all, he is an individual richly blessed with the skills to head one of the best corporations in the world today. Presently, Eric Lefkosky is the founding partner and CEO of Tempus. Tempus is a tech hub that tries to explore any available avenue so as to come up with a mechanism better suited to combat cancer.Other companies that Lefkosky has led include Lightbank, Groupon, Uptake Technologies, Mediaocean, Echo Global Logistics, and Inner Workings. Besides, Eric is the brainchild of the Lefkosky Family Foundation, and he also doubles as a trustee of Lurie Children’s Hospital, the Chicago Art Institute, and the science museum based in Chicago. Other dockets that Lefkosky holds today include chairman of Steppenwolf Theater Company, a professor at the University of Chicago, and have also authored a book titled Accelerated Disruption.
Despite his productive work ethics,Eric Lefkosky is an individual with the perfect education background. Presently, he holds a Juris doctorate that was conferred on him in his formative years at the University of Michigan Law School. Thus, he has what it takes to steer systems forward. Of all his ambitions in life, none has been greater than seeing to it that a reliable cure for cancer and breast cancer for that matter has come to fruition.
To attain a universal treatment for breast cancer, Tempus has partnered with other reputable organizations to help speed up the research process. Research is meant to establish trends that characterize many cancer patients, so as to come with a better methodology of combating the deadly ailment.Also, research on breast cancer is meant to provide a database that will help doctors understand what type of cancer they are dealing with so that they can be better placed to treat the disease. Under Eric Lefkosky’s guidance and leadership, Tempus might achieve what it is looking for sooner than we anticipate. With the additional knowledge, fewer people who have cancer will end up dying in future.